Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 7401 - 7425 of 8466 in total
Vonlerolizumab is under investigation in clinical trial NCT03029832 (A Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-based Therapy).
Investigational
Matched Description: … Vonlerolizumab is under investigation in clinical trial NCT03029832 (A Study of MOXR0916 in Combination …
AGS 16C3F is an intravenously administered, anti-ectonucleotide pyrophosphatase/phosphodiesterase 3 (ENPP3) antibody-drug conjugate. AGS-16C3F is under investigation in clinical trial NCT02639182 (A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma).
Investigational
Matched Description: … AGS-16C3F is under investigation in clinical trial NCT02639182 (A Study of AGS-16C3F vs. …
Tarcocimab tedromer is under investigation in clinical trial NCT06270836 (A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy (NPDR)).
Investigational
Matched Description: … tedromer is under investigation in clinical trial NCT06270836 (A Study to Evaluate the Efficacy and Safety of
Toluene is a colorless, liquid that is immiscible in water. It is a mono-substituted benzene derivative used in veterinary medicine as a treatment for various parasites in dogs and cats.
Vet approved
A ketotriose compound. Its addition to blood preservation solutions results in better maintenance of 2,3-diphosphoglycerate levels during storage. It is readily phosphorylated to dihydroxyacetone phosphate by triokinase in erythrocytes. In combination with naphthoquinones it acts as a sunscreening agent. [PubChem]
Experimental
Matched Description: … Its addition to blood preservation solutions results in better maintenance of 2,3-diphosphoglycerate …
105AD7 is a human monoclonal antibody that mimics the complement regulatory protein, CD55, overexpressed by many solid tumours including osteosarcoma. 105AD7 induced antitumour inflammatory responses in metastatic colorectal cancer patients. 105AD7 may be a suitable vaccine for treatment of this disease.
Investigational
Matched Description: … responses in metastatic colorectal cancer patients. 105AD7 may be a suitable vaccine for treatment of
AME-527 is a humanized monoclonal antibody that recognizes human TNF-alpha (hTNF-alpha) with high affinity and specificity. AME-527 was generated by protein engineering and identified from a library of antibody variants based on its improved binding properties.
Investigational
Matched Description: … AME-527 was generated by protein engineering and identified from a library of antibody variants based …
ARG201, a bovine-derived Type I collagen, aims to induce immune tolerance in patients with Diffuse Systemic Scleroderma (dcSSc). This drug was investigated in the completed clinical trial NCT0000567 (Multicenter Phase II Trial of Oral Type I Bovine Collagen in Scleroderma)
Investigational
Matched Description: … This drug was investigated in the completed clinical trial NCT0000567 (Multicenter Phase II Trial of
Autologous non-hematopoietic peripheral blood stem cells have been created into a formulation for use in a clinical trial (NCT04473170) by the Abu Dhabi Stem Cells Center. The cells have the characterizations of CD90+, CD133+, Oct-4+, CD45-, and CD71-.
Investigational
Matched Description: … The cells have the characterizations of CD90+, CD133+, Oct-4+, CD45-, and CD71-.[L16363] …
Vibostolimab is under investigation in clinical trial NCT04303169 (Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)).
Investigational
Matched Description: … Vibostolimab is under investigation in clinical trial NCT04303169 (Substudy 02C: Safety and Efficacy of
XL999 has the potential to provide benefit to patients with lung cancer and acute myelogenous leukemia. XL999 is a new chemical entity that inhibits a spectrum of receptor tyrosine kinases (RTKs) with growth promoting and angiogenic properties, including FGFR 1/3, PDGFRα/β, VEGFR2/KDR, KIT, and FLT3. XL999 also inhibits FLT4 and...
Investigational
Matched Description: … XL999 is a new chemical entity that inhibits a spectrum of receptor tyrosine kinases (RTKs) with growth ... growth — both directly by a novel effect on tumor cell proliferation and indirectly through inhibition of
NUC B1000 is an expressed interfering RNA (eiRNA)- based product consisting of a plasmid DNA construct designed to produce four short interfering RNA (siRNA) molecules, formulated with a proprietary cationic-lipid delivery system. eiRNA is an approach to RNAi therapeutics, whereby a plasmid DNA coding for desired dsRNA is delivered to...
Investigational
Matched Description: … NUC B1000 is an expressed interfering RNA (eiRNA)- based product consisting of a plasmid DNA construct ... On January 11, 2008, it was announced that NUC B1000 was entering a phase 1 human safety study of its …
AV-COVID-19 is a vaccine composed of autologous dendritic cells loaded with SARS-CoV-2 antigens and with or without Granulocyte-macrophage colony-stimulating factor (GM-CSF). The vaccine is created from the receiving patients’ isolated peripheral blood monocytes. The monocytes are then differentiated in vitro into dendritic cells with IL-4 and GM-CSF, incubated with SARS-CoV-2...
Investigational
Matched Description: … AV-COVID-19 is a vaccine composed of autologous dendritic cells loaded with SARS-CoV-2 antigens and with ... As of July 2020, the company is pursuing an adaptive Phase IB-II Randomized Clinical Trial (NCT04386252 …
A D-α-amino acid that is the D-isomer of arginine (only the L-form is physiologically active).
Experimental
Matched Description: … A D-α-amino acid that is the D-isomer of arginine (only the L-form is physiologically active). …
MediGene's newly acquired drug candidates MBT-0312 aim at a novel method of cancer therapy by "starving out" tumors.
Investigational
Matched Description: … MediGene's newly acquired drug candidates MBT-0312 aim at a novel method of cancer therapy by "starving …
Denibulin is a novel small molecule Vascular Disrupting Agent under development by MediciNova for treatment of solid tumor cancers.
Investigational
Matched Description: … Denibulin is a novel small molecule Vascular Disrupting Agent under development by MediciNova for treatment of
Edonerpic is a neurotrophic agent intended for the treatment of Alzheimer's disease which is under phase I clinical trial.
Investigational
Matched Description: … Edonerpic is a neurotrophic agent intended for the treatment of Alzheimer's disease which is under phase …
LY2599506 was under investigation in clinical trials NCT01024244 and NCT01029795 for the treatment of patients with type 2 diabetes.
Investigational
Matched Description: … LY2599506 was under investigation in clinical trials NCT01024244 and NCT01029795 for the treatment of
R112 is an investigational compound developed to treat Allergic Rhinitis. It's mechanism of action is to inhibit SYK kinase.
Investigational
Matched Description: … It's mechanism of action is to inhibit SYK kinase. …
Sirukumab has been used in trials studying the treatment and basic science of Giant Cell Arteritis and Arthritis, Rheumatoid.
Investigational
Matched Description: … Sirukumab has been used in trials studying the treatment and basic science of Giant Cell Arteritis and …
Crenolanib is under investigation for the treatment of Diffuse Intrinsic Pontine Glioma and Progressive or Refractory High-Grade Glioma.
Investigational
Matched Description: … Crenolanib is under investigation for the treatment of Diffuse Intrinsic Pontine Glioma and Progressive …
Dalotuzumab has been investigated for the treatment of Breast Cancer, Non Small Cell Lung Cancer, and Metastatic Colorectal Cancer.
Investigational
Matched Description: … Dalotuzumab has been investigated for the treatment of Breast Cancer, Non Small Cell Lung Cancer, and …
GW842166X has been used in trials studying the treatment of Pain, Analgesia, Inflammation, Osteoarthritis, and Pain, Inflammatory, among others.
Investigational
Matched Description: … GW842166X has been used in trials studying the treatment of Pain, Analgesia, Inflammation, Osteoarthritis …
Briciclib has been used in trials studying the treatment of Lymphoma, Neoplasms, Advanced Solid Tumor, and Acute Lymphocytic Leukemia.
Investigational
Matched Description: … Briciclib has been used in trials studying the treatment of Lymphoma, Neoplasms, Advanced Solid Tumor …
MK0893 has been used in trials studying the treatment of Type 2 Diabetes Mellitus and Diabetes Mellitus, Type 2.
Investigational
Matched Description: … MK0893 has been used in trials studying the treatment of Type 2 Diabetes Mellitus and Diabetes Mellitus …
Displaying drugs 7401 - 7425 of 8466 in total